For the meta-analyses of signature-PRS associations across cancers, we used Bonferroni correction to adjust for multiple comparisons of 115 tests, which is the total number of signature-PRS pairs, excluding those only available for breast cancer (overall, ER+, and ER−) and lung cancer (adenocarcinoma and squamous cell carcinoma). This evidence concerns the gene ESR1 and breast carcinoma.